SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on speculation that SELLASs Phase 3 REGAL AML trial is nearing its final event trigger and subsequent topline analysis, with traders reacting to CEO commentary and favorable remarks from pharmaceutical-industry professionals. The community remains sharply divided: bulls view the prolonged survival and outside commentary as supportive, while bears question the trial design, delayed event timing, and likelihood of a successful readout.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops preliminary second-quarter results and amended convertible-note exchange are driving attention, with traders weighing improved operating profitability against lower revenue, reduced cash, and dilution concerns. Unusual strength in the companys warrants has fueled speculation about a possible extension, hedging activity, or an upcoming move ahead of earnings, though no explanation is confirmed.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Celina, Texass reported conversion of its city WiFi into Helium-powered carrier coverage is driving attention, with traders viewing the deployment and broader carrier-offload use case as evidence of real-world DePIN adoption. Bullish commenters expect continued momentum, while skeptics question token dilution, hotspot profitability, and whether network usage will translate into value for HNT holders.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Anticipation of broader federal marijuana rescheduling to Schedule III, including an upcoming administrative-law recommendation, is driving attention as traders expect reduced tax burdens and improved institutional access for U.S. cannabis operators. The community remains largely bullish on Trulieves positioning and NYSE listing, while others warn that the catalyst is not yet finalized and cite profit-taking, overbought conditions, and post-earnings concerns.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Strong Phase 3 data for CAN-2409 in localized prostate cancer, along with anticipation of ASTRO findings and a planned Q4 BLA submission, is driving bullish attention. Traders see potential regulatory and pharmaceutical-partnership upside, while skeptics point to dilution risk, the unfiled BLA, profit-taking, and broader biotech momentumincluding enthusiasm around cancer-vaccine developmentsas competing factors.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Positive Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia, including substantial triglyceride reductions and fewer acute pancreatitis events, are driving attention and expectations for a broader regulatory filing. Traders are broadly bullish on REDEMPLOs commercial potential and Arrowheads RNAi platform, although some debate the valuation, competition from Ionis, and the stocks volatile sell-the-news trading.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Strait of Hormuz disruptions, tanker attacks and the broader Iran conflict are driving attention to USO, with traders debating whether constrained oil flows and low strategic reserves signal a sustained supply shock. The Venezuela oil agreement and reports of alternative shipping routes are viewed by bearish traders as potential offsets, though many argue added Venezuelan production would take years to materially affect supply.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Upcoming quarterly earnings are the dominant catalyst, with traders focused on whether Broadcoms AI custom-chip and networking demand will support stronger guidance. Bulls expect a beat and continued momentum from OpenAI and hyperscaler projects, while bears argue expectations are already elevated and remain concerned about debt, potential Google-related share loss, and another post-earnings selloff.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Canadian government funding for Xanadus quantum-manufacturing Project OPTIMISM is driving attention, while traders debate whether additional federal and Ontario support will materialize. The community is split between viewing the backing as validation of Xanadus photonic technology and warning that heavy cash burn, limited revenue, and potential dilution could offset the benefit.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Ongoing buyout speculation is the dominant topic, with traders pointing to Vandas approved products, NEREUSs potential as a GLP-1 nausea treatment, and the broader pharmaceutical M&A environment. The community remains divided, as optimism about the pipeline and perceived undervaluation competes with concerns over management, heavy spending, cash burn, and possible dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AMPX Q2 Earnings Call Highlights Higher Guidance and Drone Demand

Amprius raises 2026 revenue and margin guidance as drone demand, European sales and manufacturing economics strengthen visibility.

Amprius Technologies (AMPX) Reports Q2 Loss, Beats Revenue Estimates

Amprius (AMPX) delivered earnings and revenue surprises of 0.00% and +17.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Amprius Technologies Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Amprius Technologies, Inc. ("Amprius" or the "Company") (NYSE: AMPX), a leader in silicon anode lithium-ion batteries, today announced financial results for the second quarter ended June 30, 2026, and discussed recent business developments. Revenue for the second quarter of 2026 was $34.0 million...

Amprius Technologies Set to Report Q2 Earnings: What's in the Cards?

AMPX heads into Q2 results with revenues expected to surge 92.6% y/y, fueled by customer wins and rising SiCore battery adoption.

Duos Technologies Group, Inc. (DUOT) Moves 5.8% Higher: Will This Strength Last?

Duos Technologies Group, Inc. (DUOT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Amprius Technologies Sets Upcoming Conference Schedule

Amprius Technologies, Inc. ("Amprius"), (NYSE: AMPX), a leader in silicon anode lithium-ion batteries, today announced that it will participate in the upcoming conferences:Canaccord Genuity 46th Annual Growth ConferenceDate: Aug. 11-12, 2026Location: InterContinental Boston; Boston, MAEvent...

Amprius Technologies Becomes Oversold (AMPX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Amprius Technologies Announces Date for Second Quarter 2026 Results and Business Updates

Amprius Technologies, Inc. ("Amprius"), (NYSE: AMPX), a leader in silicon anode lithium-ion batteries, will hold a conference call and webcast on Wednesday, August 5, 2026, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time) to discuss its financial results for the second quarter ended June 30...

Cramer's lightning round: Buy Amprius Technologies

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...

New Strong Sell Stocks for July 7th

AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.

• Reported GAAP EPS of -$0.04 up 20.00% YoY
• Reported revenue of $34.03M up 125.87% YoY
• Amprius Technologies expects 2026 total revenue of at least $140 million, gross margin of at least 28%, net loss of less than $10 million, and positive Adjusted EBITDA of at least $4 million.

Amprius Technologies reported a GAAP net loss for the quarter, significant cash outflows from operations, and identified material risks related to supply chain disruptions and the execution of its contract manufacturing strategy.

Amprius Technologies delivered record revenue growth and expanded gross margins, supported by significant new customer contracts and the ongoing advancement of its pilot line and contract manufacturing capacity expansion initiatives.

Amprius Technologies (NYSE: AMPX) is at the forefront of transforming electric mobility with its revolutionary Silicon Anode lithium-ion battery. The company is powering a new era, offering a drop-in replacement for conventional lithium-ion batteries while delivering up to 80% higher energy density. Leveraging its patented silicon anode platform, the company’s commercially proven batteries deliver unmatched performance – ultra-high energy density, high power density, extreme fast charge rate capability, wide operating temperature, and long cycle life.

Amprius Technologies Inc

Why Did Amprius Stock Surge Over 11% Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMPX Amprius Technologies Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest AMPX News